Coloplast A/S Class B

Coloplast A/S Class B

7.46
USD
-0.03
(-0.40%)
0.21EPS
30.44P/E
14.19BMarket Cap
Feb 09Next Earn

Total Valuation

USD

As of September 30, 2026, Coloplast AS carries a market capitalization of 14.19B, placing it among publicly traded companies globally. Its enterprise value stands at 17.38B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap14.19B
Enterprise Value17.38B

Important Dates

Coloplast AS's next confirmed earnings release is scheduled for February 9, 2027.

Earnings Date2/9/2027

Share Statistics

As of September 30, 2026, Coloplast AS has 2.25B shares outstanding.

Shares Outstanding2.25B

Valuation Ratios

As of September 30, 2026, Coloplast AS trades at a trailing price-to-earnings ratio of 30.44. The price-to-sales ratio is 3.23, and the price-to-book ratio stands at 6.55.

PE Ratio30.44
PS Ratio3.23
PB Ratio6.55
P/TBV Ratio-7.48
P/FCF Ratio14.54
P/OCF Ratio11.69

Enterprise Valuation

As of September 30, 2026, Coloplast AS trades at an EV/EBITDA multiple of 9.67 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 3.96 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 15.43 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Coloplast AS trades at an EV/FCF ratio of 16.09, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 17.38B versus a market cap of 14.19B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales3.96
EV / EBITDA9.67
EV / EBIT15.43
EV / FCF16.09

Financial Position

As of September 30, 2026, Coloplast AS maintains a current ratio of 0.74, meaning it holds 0.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 150.56, indicating elevated leverage, while an interest coverage ratio of 13.77 demonstrates strong ability to service its debt obligations.

Current Ratio0.74
Quick Ratio0.04
Debt / Equity150.56
Debt / EBITDA1.81
Interest Coverage13.77

Financial Efficiency

USD

These figures cover the twelve months ended September 30, 2026. The company generates approximately 257,169.86 in revenue per employee across its workforce of 17,061.25, a quick read on workforce productivity versus industry peers.

Revenue Per Employee257,169.86
Employee Count17,061.25

Taxes

USD

Over the twelve months ended September 30, 2026, Coloplast AS recorded 117.49M in income tax expense. That works out to an effective tax rate of 20.14, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 583.53M, leaving 466.04M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Income Tax117.49M
Effective Tax Rate20.14

Stock Price Statistics

USD

As of the close on November 16, 2026, Coloplast AS's stock has declined approximately 18.74% over the past 52 weeks. The 50-day moving average sits at 6.88, while the 200-day moving average is 6.73.

52-Week Price Change-18.74%
50-Day Moving Average6.88
200-Day Moving Average6.73

Income Statement

USD

Over the twelve months ended September 30, 2026, Coloplast AS generated 4.39B in revenue and converted that into 466.04M in net income, yielding earnings per share of 0.21. EBITDA reached 1.80B, while operating income came in at 1.13B.

Revenue4.39B
Gross Profit2.92B
Operating Income1.13B
Pretax Income583.53M
Net Income466.04M
EBITDA1.80B
EBIT1.13B
Earnings Per Share (EPS)0.21

Balance Sheet

USD

As of September 30, 2026, Coloplast AS holds 77.47M in cash and equivalents against 3.26B in total debt, resulting in a net debt position of 3.02B. Total book value stands at 2.17B, with working capital of -532.74M providing operational flexibility.

Cash & Cash Equivalents77.47M
Total Debt3.26B
Net Debt3.02B
Equity (Book Value)2.17B
Book Value Per Share0.96
Working Capital-532.74M

Cash Flow

USD

Coloplast AS produced 1.21B in operating cash flow over the twelve months ended September 30, 2026. After subtracting -238.02M in capital expenditures, free cash flow totaled 975.74M - equivalent to 0.43 per share.

Operating Cash Flow1.21B
Capital Expenditures-238.02M
Free Cash Flow975.74M
FCF Per Share0.43

Margins

Over the twelve months ended September 30, 2026, Coloplast AS posted a gross margin of 66.50, reflecting its pricing power and cost economics. The operating margin of 25.73 and net profit margin of 10.62 provide insight into operational efficiency.

Gross Margin66.50
Operating Margin25.73
Pretax Margin13.30
Profit Margin10.62
EBITDA Margin40.97

Dividends & Yields

USD

Over the twelve months ended September 30, 2026, Coloplast AS paid dividends of 0.35 per share. The dividend payout ratio of 168.61 exceeds 100%, meaning the company is distributing more than it earns and funding the dividend from cash reserves, asset sales, or borrowing, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 6.88, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 7.21, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Coloplast AS shareholders.

Dividend Per Share0.35
Payout Ratio168.61
Shareholder Yield7.21
FCF Yield6.88

Stock Splits

Coloplast AS's most recent stock split took place on June 25, 2013 with a 1:5 split ratio.

Last Split Date6/25/2013
Split Ratio1:5

Scores

As of September 30, 2026, Coloplast AS has an Altman Z-Score of 5.13, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score5.13